Read More

Milestone Pharmaceuticals Announces New Data from Phase 3 RAPID Trial Of Etripamil Nasal Spray in Patients with PSVT During Late-Breaking Session At AHA Scientific Sessions 2022; Says Trial Met Primary Endpoint

Trial met its primary endpoint, with 64.3% of patients receiving etripamil converting to sinus rhythm within 30 minutes compared to 31.2% on placebo (HR = 2.62, p<0.001) Median time to

MIST